Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
Anticancer Research · 2024
DOI: 10.21873/anticanres.17123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Shohei Komatsu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; komasho8@med.kobe-u.a…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Quinolines, Phenylurea Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Sorafenib and lenvatinib have long been used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Along with the development of systemic chemotherapy for HCC, the concept of conversion hepatectomy has recently become widespread. The present study aimed to assess the clinical outcomes of sorafenib and lenvatinib for HCC regarding the possibility of conversion hepatectomy in clinical practice. PATIENTS AND METHODS: A total of 295 patients with advanced HCC receiving sorafenib and lenvatinib, accounting for 306 treatments (sorafenib, n=157; lenvatinib, n=149, 11 patients received lenvatinib after sorafenib treatment) at five different institutions were enrolled. Patients were assessed for their clinical characteristics and therapeutic response using both Response Evaluation Criteria in Solid Tumors criteria (RECIST) and modified RECIST (mRECIST) criteria. Additionally, an indication of surgery after tyrosine kinase inhibitor administration was determined based on the tumor status of patients. RESULTS: The median survival times of patients treated with sorafenib and lenvatinib were 12.8 and 16.4 months, respectively, without significant difference (p=0.1645). The objective response rates (ORR) of sorafenib based on mRECIST and RECIST were 10.1% and 5.9%, respectively, and those of lenvatinib were 38.1% and 19.0%, respectively. Among the 306 treatments, two cases (sorafenib and lenvatinib, one each) underwent hepatectomy after systemic chemotherapy. CONCLUSION: Few cases with unresectable HCC were amenable to conversion hepatectomy after sorafenib and lenvatinib treatments due to the limited ORR by RECIST. Cautious approach must be taken when administering neoadjuvant chemotherapy aimed at conversion hepatectomy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; komasho8@med.kobe-u.ac.jp.
- Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Gastroenterology, Kakogawa Central City Hospital, Hyogo, Japan.
- Department of Gastroenterology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
- Department of Gastroenterology, Yodogawa Christian Hospital, Osaka, Japan.
- Department of Gastroenterological Surgery, Hyogo Cancer Center, Hyogo, Japan.
Zitieren
APA
Komatsu, S., Yano, Y., Mimura, T., Minami, A., Momose, K., Hirano, H., Tanaka, M., Ueda, Y., Tai, K., Yasuhara, Y., Nakagawa, D., Yamamoto, A., Kido, M., Ueda, Y., Kodama, Y., & Fukumoto, T. (2024). Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17123
Vancouver
Komatsu S, Yano Y, Mimura T, Minami A, Momose K, Hirano H, et al. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. Anticancer Research. 2024. doi:10.21873/anticanres.17123
BibTeX
@article{Komatsu2024,
author = {Komatsu, Shohei and Yano, Yoshihiko and Mimura, Takuya and Minami, Akihiro and Momose, Kenji and Hirano, Hirotaka and Tanaka, Motofumi and Ueda, Yuki and Tai, Kentaro and Yasuhara, Yuki and Nakagawa, Daisuke and Yamamoto, Atsushi and Kido, Masahiro and Ueda, Yoshihide and Kodama, Yuzo and Fukumoto, Takumi},
title = {Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17123}
}
EUVIMED